The about-$1 billion deal could come imminently.

Here's how we employ swing trading strategies of selling into strength, selling into weakness and cutting a loss quickly.

Eli Lilly (LLY 3.74%) is close to doing something no other pharmaceutical company has ever done: reaching $1 trillion in ...

Schrödinger (SDGR) and Revvity (RVTY) on Friday announced collaborations with Eli Lilly (LLY) to integrate their respective ...

Eli Lilly has the lead in the GLP-1 race, but Novo Nordisk just changed the game.

Eli Lilly said Thursday that adding its weight loss drug Zepbound on top of its immunology therapy Taltz helped obese ...

Eli Lilly and Company rated Buy: incretin/obesity growth, ZEPBOUND & orforglipron access strategy, pipeline deals, ...

Eli Lilly is considering all these risks and planning accordingly, and doing so years in advance. That's also why the ...

Ventyx Biosciences shares rose 29% after The Wall Street Journal reported that the company is in advanced talks to be ...